NCT00380653View on ClinicalTrials.gov

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

June 30, 2009

Conditions

LeukemiasMyelodysplastic Syndromes

Interventions

DRUG

sapacitabine

Trial Locations (1)

77030-4009

The University of Texas MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Cyclacel Pharmaceuticals, Inc.

All Listed Sponsors

lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT00380653 - Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter